Paller et al. evaluated the long-term efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis through the 52-week Phase III SPROUT trial. The study assessed whether clinical responses were sustained after the placebo-controlled period and whether outcomes differed between treatment sequences.

Prajapati et al. conducted the PROTOSTAR trial to assess guselkumab in paediatric patients with moderate-to-severe plaque psoriasis. Guselkumab significantly improved skin clearance versus placebo at Wk16, with high response rates sustained through Wk52 and a favourable safety profile.